Importing Quality Oncology Medicines for Pakistan
Uniphar Pakistan imports high-quality oncology products from trusted international manufacturers — improving access, affordability and reliable supply for patients and healthcare institutions.
From qualified manufacturers to Pakistani hospitals
Every product follows a disciplined pathway built on qualified manufacturing, regulatory compliance and dependable supply.
- Step 1
Source
Partner with qualified international manufacturers, including Varifarma and Kemex in Argentina.
- Step 2
Register
Product registration and import approvals with the Drug Regulatory Authority of Pakistan (DRAP).
- Step 3
Import
Import, clearance and compliant storage and handling of oncology products.
- Step 4
Supply
Reliable supply to hospitals, cancer centres, institutions and distribution partners.
Oncology, biosimilars & specialty medicines
Oncology
Chemotherapy, targeted therapies, onco-hematology and supportive care.
Biosimilars & complex biologics
Oncology biosimilars, monoclonal antibodies and complex molecules.
Specialty pharmaceuticals
Selected differentiated specialty and hospital medicines.
Product availability, licensing rights, registration status and territory rights are confirmed market by market. Individual products remain subject to regulatory approval, licensing and commercial arrangements in each territory.
Oncology
Oncology is the principal therapeutic focus of Uniphar Pakistan.
We aim to build a comprehensive and commercially sustainable portfolio covering established chemotherapy products, targeted therapies, supportive care and selected innovative or specialty treatments.
- Oncology injectables
- Oral oncology medicines
- Targeted and specialty therapies
- Onco-hematology
- Supportive-care products
- Hospital and institutional oncology products
Biosimilars & Complex Biologics
Uniphar is developing opportunities in biosimilars and complex biologic therapies through international partnerships and portfolio development.
The focus is on products where strong scientific, regulatory and commercial capabilities can create sustainable access.
- Oncology biosimilars
- Monoclonal antibodies and complex biologics
- Selected specialty biologic therapies
- Future opportunities in high-value complex molecules
Specialty Pharmaceuticals
Alongside oncology and biosimilars, Uniphar evaluates selected specialty medicines where differentiated products, reliable manufacturing and disciplined market access can create meaningful healthcare impact.
- Differentiated products
- Reliable manufacturing
- Disciplined market access
- Meaningful healthcare impact
Explore a Partnership
Let’s build the next generation of specialty pharmaceutical opportunities together.